文献速递银屑病与炎症性皮肤病

银屑病患者乌司奴单抗停药后复发时间预测因素:8年多中心研究

Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study.
PubMed 文献 · J Am Acad Dermatol · 2019-01-29

该研究筛查2011至2018年间接受乌司奴单抗治疗的500例银屑病患者(共669个治疗疗程),纳入其中202例对治疗有应答并停药的患者(共304个疗程)。停药后6、12、18、24和36个月无复发累积概率分别为49.3%、12.6%、5.3%、4.7%和1.6%。多因素分析显示,生物制剂初治状态、治疗期间PASI最大改善程度、达到PASI50所需时间、银屑病家族史、慢性肾病及未用乌司奴单抗期间使用免疫抑制剂是复发时间的显著预测因素。

要点

  • 乌司奴单抗停药后复发率高,36个月无复发概率仅1.6%。
  • 生物制剂初治、PASI改善程度高及达PASI50时间短与复发时间相关。
  • 银屑病家族史、慢性肾病及停药期间使用免疫抑制剂也是预测因素。

核心结论

  • 鉴于复发率高,不建议对控制良好的银屑病患者停用乌司奴单抗。

研究设计与样本

  • 多中心回顾性研究,筛查500例银屑病患者(669个治疗疗程),纳入202例应答后停药患者(304个疗程)。

主要发现

  • 停药后6、12、18、24和36个月无复发累积概率分别为49.3%、12.6%、5.3%、4.7%和1.6%。
  • 多因素回归显示生物制剂初治状态、治疗期间PASI最大改善、达到PASI50时间、银屑病家族史、慢性肾病及免疫抑制剂使用是复发时间的显著预测因素。

临床怎么用

  • 临床应避免对乌司奴单抗控制良好的银屑病患者贸然停药,需综合评估预测因素。

局限性

  • 治疗持续时间和随访为非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on predictors and time to relapse in patients with psoriasis who discontinue therapy in a real-world setting are scarce. OBJECTIVE: To investigate predictors of relapse after withdrawal of ustekinumab in patients with psoriasis. METHOD: This study screened 500 patients with psoriasis who received ustekinumab (669 treatment episodes) between 2011 and 2018. Overall, 202 patients (accounting for 304 treatment episodes) who had responded to therapy and were withdrawn from ustekinumab treatment were included. RESULTS: The cumulative probabilities of being relapse-free at 6, 12, 18, 24, and 36 months after withdrawal from ustekinumab treatment were 49.3%, 12.6%, 5.3%, 4.7%, and 1.6%, respectively. Multivariate regression analyses with a generalized estimating equation showed that after adjustments, biologic-naive status, maximum improvement in Psoriasis Area and Severity Index during ustekinumab treatment, time to achieve a 50% improvement in baseline Psoriasis Area and Severity Index score after initiation of ustekinumab, family history of psoriasis, chronic kidney disease, and immunosuppressant use while not taking ustekinumab were significant predictors of time to relapse following discontinuation of ustekinumab. LIMITATION: Nonrandomized allocation of duration of treatment and follow-up. CONCLUSION: Given the high rates of relapse, withdrawal of ustekinumab from patients with well-controlled psoriasis cannot be recommended.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study. J Am Acad Dermatol. 2019. PMID: 30703455. doi:10.1016/j.jaad.2019.01.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。